WO2019045286A2 - Composition comprenant de la miquelianine en tant que principe actif pour la prévention ou le traitement d'une maladies immunitaire médiée par th2 - Google Patents

Composition comprenant de la miquelianine en tant que principe actif pour la prévention ou le traitement d'une maladies immunitaire médiée par th2 Download PDF

Info

Publication number
WO2019045286A2
WO2019045286A2 PCT/KR2018/008664 KR2018008664W WO2019045286A2 WO 2019045286 A2 WO2019045286 A2 WO 2019045286A2 KR 2018008664 W KR2018008664 W KR 2018008664W WO 2019045286 A2 WO2019045286 A2 WO 2019045286A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mediated immune
interleukin
miquelianin
present
Prior art date
Application number
PCT/KR2018/008664
Other languages
English (en)
Korean (ko)
Other versions
WO2019045286A3 (fr
Inventor
신희순
이소영
박소림
남영도
서동호
엄지은
최대운
신동욱
정선영
손동화
연성흠
손락호
필감방
Original Assignee
한국식품연구원
(주)휴온스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180088860A external-priority patent/KR102109503B1/ko
Application filed by 한국식품연구원, (주)휴온스 filed Critical 한국식품연구원
Publication of WO2019045286A2 publication Critical patent/WO2019045286A2/fr
Publication of WO2019045286A3 publication Critical patent/WO2019045286A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a composition for preventing or treating a Th2-mediated immune disorder, comprising miquelin as an active ingredient, and the like.
  • Allergy is a disease caused by a malfunction of the immune system, which causes irritation such as urticaria, itching, runny nose, and cough in a specific person. It is caused by environmental pollution, westernization of diet and lifestyle, , ≪ / RTI > and various allergens. Twenty to 25 percent of the world's population is exposed to allergic diseases, and the prevalence of this disease continues to rise.
  • type I-type III is a humoral immune response (immediate type) involving antibodies
  • type IV is a cell-mediated immune response Delay type.
  • Most allergic reactions are type I, and are typical diseases such as asthma, rhinitis, conjunctivitis, food and drug allergy, and atopic dermatitis. In severe cases, anaphylaxis may occur.
  • the type I immediate-type hypersensitivity reaction is divided into two stages.
  • the Th1 cell reaction which produces IL-12 and IFN- ⁇ which suppresses the secretion of IgE and IgG1 by the invasion of the allergen and increases the secretion of IgG2a
  • Th2 type 2 helper T
  • IgE-specific antibodies produced by B cells are attached to the surface of mast cells or basophils, and allergens are sensitized to allergens.
  • the second stage of the allergic manifestation is divided into an initial reaction and a late reaction.
  • the initial reaction re-enters the body to stimulate mast cells and triggers the degranulation reaction.
  • the vasodilation by histamine, lipid metabolites, cytokines, And late response is activated by infiltration of neutrophils, eosinophils, macrophages, Th2 cells, basophils, and the like in the tissues, thereby causing inflammation and causing atopic dermatitis, rhinitis and asthma.
  • Histamine is one of the most well-known factors in the deglycosyltransferase, and is associated with immediate hypersensitivity reactions and is thus used as an important indicator of allergy symptoms.
  • the present invention has been conceived to solve the above-mentioned problems.
  • the present inventors have made intensive studies to improve the preventive or therapeutic effect of a disease caused by a Th2 immune response such as an allergy, and found that miquelianin (IL-2) interleukin-4 (IL-4), interleukin-5 (IL-5), and / or interleukin-13 (IL-13) T cell proliferation inhibitory effect.
  • IL-2 miquelianin
  • IL-4 interleukin-4
  • IL-5 interleukin-5
  • IL-13 interleukin-13
  • an object of the present invention is to provide a pharmaceutical composition for preventing or treating a Th2-mediated immune disease, comprising miquelianin as an active ingredient.
  • Another object of the present invention is to provide a composition for preventing or ameliorating a Th2-mediated immune disease, comprising miquelianin as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating a Th2-mediated immune disease comprising miquelianin as an active ingredient.
  • the present invention also provides a composition for preventing or ameliorating a Th2-mediated immune disease, comprising miquelianin as an active ingredient.
  • the Th2-mediated immune disease may be an allergic disease.
  • the composition may inhibit T cell proliferation.
  • the composition may inhibit IgE (immunoglobulin E) production.
  • the composition for preventing or ameliorating the Th2-mediated immune disease may be a food composition or a cosmetic composition.
  • the food composition may be a health functional food composition.
  • the present invention provides a method for preventing or treating a Th2-mediated immune disease comprising administering to a subject a pharmaceutical composition comprising miquelianin as an active ingredient.
  • the present invention also provides the use of a pharmaceutical composition comprising miquelianin as an active ingredient for preventing or treating a Th2-mediated immune disease.
  • composition according to the present invention was found to be excellent in antiallergic effect by containing meculiene as an active ingredient.
  • IL-4 interleukin-5
  • IL-2 interleukin-13
  • the composition according to the present invention is expected to be useful for the development of therapeutic agents for the prevention, improvement, or treatment of Th2-mediated immune diseases, food for improving immunological diseases, and cosmetics.
  • Figure 1 is a pictorial representation of a protocol for evaluating the efficacy of miquelianin in an allergic contact dermatitis mouse assay system using TMA (trimellitic anhydride).
  • FIG. 2A is a graph showing changes in the thickness of the mouse ear to examine the effect of Miquelin in mice treated with TMA.
  • FIG. 2B is a microscopic observation of the ear tissue of a mouse treated with TMA.
  • FIGS. 3A and 3B show the effect of Miquelian on TMA-treated mice by ELISA method to determine the amount of IgE (FIG. 3A) and IL-4, IL-5 and IL-13 (FIG. 3B) .
  • FIG. 4 shows T cell proliferation by MTT (3- (4,5-diethyl thiazol-2-yl) -2,5-diphenyl tetrazolium bromide) method in order to examine the effect of myquelian on TMA- .
  • FIG. 5 is a diagram illustrating a protocol for evaluating the efficacy of myquelian for a mouse in which an allergic immune response is induced by ovalbumin (OVA) immunity.
  • OVA ovalbumin
  • FIGS. 6A and 6B are graphs showing the effect of Miquelian on the allergic immune response induced by OVA immunization.
  • IL-2 IL-2
  • IL-4 IL-
  • IL- Fig. 6B
  • FIG. 7 shows the results of measurement of T cell proliferation by MTT assay in order to examine the effect of Miquelin in mice in which allergic immunity was induced by OVA immunization.
  • FIG. 8 shows the results of analysis of the amounts of IL-2, IL-4, IL-5 and IL-13 produced by the ELISA method in order to examine the effect of Miquelin for splenocytes in mice allergic to the OVA immunization to be.
  • FIG. 9 shows the results of measurement of T cell proliferation by MTT assay in order to examine the effect of Miquelin for spleen cells of mice in which allergic immunity was induced by OVA immunization.
  • Figure 10 shows the result of using the MTT assay to assess the effect of the non US kwelri for CD4 + T cell proliferation, measuring the proliferation of CD4 + T cells.
  • the present inventors have completed the present invention by confirming that miquelianin has Th2 immunosuppressive activity and T cell proliferation inhibitory activity.
  • the present invention provides a pharmaceutical composition for preventing or treating a Th2-mediated immune disease, comprising miquelianin as an active ingredient.
  • prophylactic means any action that inhibits or delays the onset of Th2-mediated immune disease by administration of the composition according to the present invention.
  • treatment refers to any action that improves or alters the symptoms of a Th2-mediated immune disorder by administration of the composition of the present invention.
  • T cell refers to an IL-4, an IL-5, an IL-6, a Th1 cell producing interleukin-2 (IL- , IL-10, IL-13, and the like.
  • the immune balance regulated by cytokines produced by these Th1 and Th2 cells is called the Th1 / Th2 balance.
  • Th1 cells are important for the regulation of cellular immunity, and Th2 cells are known to play an important role in the regulation of humoral immune. In normal conditions, the Th1 / Th2 balance is maintained while interfering with IFN- ⁇ -mediated cytokine, which is important for Th1 differentiation, and cytokine mainly IL-4, which is important for Th2 differentiation.
  • Th1 / Th2 balance when the Th1 / Th2 balance is broken, various immune diseases can be induced.
  • the cellular immunity In the case of deflecting Th1, the cellular immunity is revived to increase the resistance to infection.
  • Th2 When the Th2 is deflected, the infection resistance is decreased. Conversely, do.
  • Th2-mediated immune disease which is a disease targeted by the present invention, refers to a disease in which IgE and mast cells are involved in the production and activity of allergens, particularly Th2 cells.
  • diseases include allergies, Skin diseases including dermatitis, acute and chronic allergic rhinitis, asthma, food allergies, and the like.
  • the degree of increase in ear thickness was relatively smaller than that in the group treated with TMA alone, and the higher the concentration of treated myquelian, the higher the IgE , IL-4, IL-13, and IL-5 production was low and T cell proliferation was further inhibited (see Example 2).
  • the amount of IgE, IL-2, IL-4, IL-5, and IL-13 produced in mice treated with OVA and Miquelin was lower than that of OVA alone It was also confirmed that cell proliferation was also inhibited (see Example 3).
  • the amount of IL-2, IL-4, IL-5, and IL-13 produced by the mice treated with OVA and myquelien in spleen cells of mice was lower than that of the mice administered with OVA only , And it was confirmed that the inhibitory effect was greater when the concentration of myquelianin was higher in T cell proliferation (see Example 4).
  • composition of the present invention specifically confirmed the improvement, prevention, or therapeutic effect of Th2-mediated immune diseases.
  • the pharmaceutical composition according to the present invention contains miquelianin as an active ingredient and may further comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carriers are those conventionally used in the field of application and include, but are not limited to, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, And may further contain other conventional additives such as antioxidants and buffers as needed.
  • injectable formulations pills, capsules, granules or tablets
  • aqueous solutions such as aqueous solutions, suspensions, emulsions and the like
  • Suitable pharmaceutically acceptable carriers and formulations can be suitably formulated according to the respective ingredients using the methods disclosed in Remington's reference.
  • the pharmaceutical composition of the present invention is not particularly limited to a formulation, but may be formulated into injections, inhalants, external skin preparations, and the like.
  • the pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may vary depending on the condition and the weight of the patient, The mode of administration, the route of administration, and the time, but may be appropriately selected by those skilled in the art.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • a pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment.
  • the effective dose level is determined depending on the type of disease, severity, drug activity, , The time of administration, the route of administration and rate of excretion, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts.
  • the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, sequentially or concurrently with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
  • the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, body weight, absorbency of the active ingredient, inactivity and excretion rate of the patient, type of disease, The severity, sex, weight, age, etc. of the subject.
  • composition for preventing or ameliorating a Th2-mediated immune disease comprising miquelianin as an active ingredient.
  • the composition may comprise a food composition or a cosmetic composition.
  • the food composition may comprise a health functional food composition.
  • the term " improvement" means all actions that at least reduce the degree of symptom associated with the condition being treated.
  • the food composition may be used either simultaneously with or separately from the agent for treatment before or after the onset of the disease for the improvement of the Th2-mediated immune disease.
  • the term food composition used in the present invention may be formulated into one selected from the group consisting of tablets, pills, powders, granules, powders, capsules, and liquid formulations, including one or more of carriers, diluents, excipients, .
  • Examples of foods that can be added to the extract of the present invention include various foods, powders, granules, tablets, capsules, syrups, drinks, gums, tea, vitamin complexes, and health functional foods.
  • Examples of the additive that can be further included in the present invention include natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors and the like), colorants, fillers, At least one component selected from the group consisting of alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents and fats can be used.
  • Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • natural flavors tactatin, stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used.
  • composition according to the present invention can be used in various forms such as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies, factic acid and its salts, alginic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, etc.
  • Other compositions according to the present invention may contain flesh for the production of natural fruit juices and vegetable drinks . These components may be used independently or in combination.
  • carrier examples include, but are not limited to, lactose, dextrose But are not limited to, sucrose, sorbitol, mannitol, erythritol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylquilolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water , At least one selected from the group consisting of sugar syrup, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil is preferably used.
  • the cosmetic composition of the present invention may contain not only miquelianin but also ingredients conventionally used in cosmetic compositions and may contain conventional ingredients such as antioxidants, stabilizers, solubilizers, vitamins, pigments, Adjuvants, and carriers.
  • the composition of the present invention may be mixed with an organic UV blocking agent that has been used in the past so long as it does not impair the skin protecting effect by reacting with miquelianin.
  • organic UV blocking agent include glyceryl paraben, drometrizol trisiloxane, drometrizol, dipaloyyl triolate, disodium phenyldibenzimidazole tetrasulfonate, diethylhexylbutamidotriazone, diethylamino Hydroxybenzoylhexyl benzoate, di-methoxycinnamate, a mixture of Rawson and dihydroxyacetone, methylene bis-benzotriazolyltetramethylbutylphenol, 4-methylbenzylidene camphor, menthyl anthranylate, benzophenone (Benzophenone-4), benzophenone-8 (dioxyphenylbenzone), butylmethoxydibenz
  • Examples of products to which the cosmetic composition of the present invention can be added include cosmetics such as astringent lotion, softening longevity lotion, nutrition lotion, various creams, essences, packs, foundation and the like, cleansing, cleanser, soap, .
  • Specific formulations of the cosmetic composition of the present invention include skin lotions, skin softeners, skin toners, astringents, lotions, milk lotions, moisturizing lotions, nutritional lotions, massage creams, nutritional creams, moisturizing creams, hand creams, essences, It includes formulations such as soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, latex, lipstick, makeup base, foundation, press powder, loose powder, eye shadow and the like.
  • the content of miquelianin of the present invention is 0.00001-30 wt%, preferably 0.5-20 wt%, more preferably 1.0-10 wt% %to be.
  • Example 1-1 Analysis of cytokines using ELISA
  • ELISA assay kits for cytokine BD science were used for IgE, IL-2, IL-4 and IL-5, and IL-13 was used for ELISA assay kit from R & D.
  • a capture antibody was added to a 96-well plate, and the plate was reacted overnight at 4 ° C.
  • the plate was coated with an antibody, washed with a phosphate buffered saline with Tween 20 (PBST) assay diluent, 10% FBS in PBS) was added to each well and incubated at room temperature for 1 hour for blocking.
  • PBST phosphate buffered saline with Tween 20
  • 100 ⁇ l of a standard solution and a mouse spleen cell culture solution were dispensed into each well, followed by reaction at room temperature for 2 hours.
  • HRP streptavidin-Horseradish peroxidase
  • a specific primary antibody capable of detecting each cytokine was dispensed into each well and incubated at room temperature for 1 Lt; / RTI > Then, 100 ⁇ l of a substrate solution (0.01% TMB in phosphate-citrate buffer) was added and developed at room temperature for 30 minutes. Then, 50 ⁇ l of 2 M H 2 SO 4 was added to each well to stop the color reaction. The absorbance was measured with a microplate reader at.
  • the cells were cultured in a 96-well plate at a final volume of 200 ⁇ L according to the cell treatment conditions of the experiment prepared in each of the examples.
  • MTT 3- (4,5-diethyl thiazol-2 -yl) -2,5-diphenyl tetrazolium bromide) reagent was treated with 20 ⁇ L each well. Next, after 4 hours, 100 ⁇ L of 10% SDS was added to each well, reacted overnight, and then measured at 570 nm absorbance.
  • mice Six-week old BALB / c mice were treated with 50 ⁇ L of TMA (5%) dissolved in acetone and isopropylmyristate (4: 1) on the lateral side of the hairy mouse (day 0) 10 ⁇ L of TMA (2%) was treated on each day of each day from day 0 to day 14.
  • 20 ⁇ L of each of 4 mg / mL and 10 mg / mL of myquelion and 1 mg / mL of dexamethasone as a positive control were treated with TMA treatment for 1 hour from day 0 to day 14, Ear thickness of the mouse was observed up to 15 times.
  • the left ear was fixed to 10% formaldehyde to cut the 6 mm-thick section.
  • the sections were stained with hematoxylin and 0.5% eosin (hematoxylin and eosin [H & E] staining) to examine tissue section and skin cell infiltration. Tissue sections were imaged using a Leica DM5000B fluorescence microscope.
  • the group treated with TMA and myquelinia showed a relatively small increase in the thickness of the mouse ear compared to the group treated with TMA alone.
  • FIG. 2B It was confirmed that the thickness of the tissue was thinner than that of TMA alone when treated with TMA and Miquelin.
  • mice After the mice were treated up to Day 14 as in Example 2-1, the serum and draining lymph nodes of the mice were harvested on Day 15, and the serum was analyzed by IgE analysis, ear tissue and monocellular draining lymph node was cultured in CO 2 incubator for 48 hours with concanavalin A (2 ⁇ g / mL) in RPMI (10% FBS) medium at 1 ⁇ 10 6 cells / mL, -1 < / RTI > ELISA assay.
  • concanavalin A (2 ⁇ g / mL) in RPMI (10% FBS) medium at 1 ⁇ 10 6 cells / mL, -1 < / RTI > ELISA assay.
  • IgE (FIG. 3A) and IL-4, IL-5, and IL-13 (FIG. 3B) were more potent than TMA alone when TMA and Miquelin were administered together. All of them showed low production, and the higher the concentration of myquelianin, the lower the production of cytokine.
  • T cell proliferation was measured by the MTT method of Example 1-2.
  • T cell proliferation was lower than that of TMA alone, and it was found that the higher the Miquelian concentration, the lower the proliferation rate .
  • Example 3-1 Observation of cytokine and IgE production
  • Allergic immune responses were induced by intraperitoneal injection of 10 ⁇ g of OVA and 1 mg of alum at day 0 and day 14 on 6-week-old BALB / c mice, and 2 ⁇ g / kg of mechelian from day 7 to day 21 Orally administered at a concentration of 4 mg / kg.
  • dexamethasone 2.5 mg / kg was orally administered for the same period of time as the myquelien group, and mouse serum and spleen cells were extracted on day 22. Serum was used for IgE measurement.
  • Each group of spleen cells was monoclonalized and cultured in a CO 2 incubator with OVA (100 ⁇ g / mL) at 5 ⁇ 10 6 cells / mL for 72 hours using RPMI (10% FBS) , And the supernatant was collected and used for Th2 cytokine analysis using the ELISA method of Example 1-1.
  • FIGS. 6A and 6B when mice were administered with OVA and Myquelian, IgE (FIG. 6A) and IL-4, IL-5, IL-13 and IL -2 (Fig. 6B).
  • T cell proliferation was measured by the MTT method of Example 1-2 using the spleen cells cultured as in Example 3-1.
  • splenocytes were harvested and used for experiments. Thereafter, the spleen cells were unilamellarized and cultured in RPMI (10% FBS) medium at 5 ⁇ 10 6 cells / mL with OVA (100 ⁇ g / mL) and Miquelin with concentrations of 6.25 ⁇ g, 12.5 ⁇ g, 25 ⁇ g and 50 ⁇ g And cultured in a CO 2 incubator for 72 hours. The supernatant was collected and used for Th2 cytokine analysis using the ELISA method of Example 1-1.
  • IL-2, IL-4, IL-5, and IL-13 production was lower in the group treated with OVA and Miquelin in splenocytes than in the group treated with OVA alone It was confirmed that the higher the concentration of myquelian, the lower the production amount.
  • T cell proliferation was assayed by using the MTT assay of Example 1-2 on spleen cells cultured as in Example 4-1.
  • T cell proliferation was inhibited in the group treated with OVA and myquelianin in spleen cells, and that in the group treated with OVA was suppressed. Respectively.
  • CD4 + T cells were isolated from spleen cells of BALB / c mice using MagniSort TM Mouse CD4 T cell Enrichment Kit. Separated CD4 + T cells were treated with 1 ⁇ 10 6 cells / mL in RPMI (10% FBS) medium in a 96 well plate coated with CD3 anti-body (1 ⁇ g / mL) CD28 anti-body (1 ⁇ g / mL) and cultured for 48 hours. The proliferation of CD4 + T cells was measured using the MTT method of Example 1-2.
  • the composition according to the present invention can contribute to the development of the medical industry for the prevention, improvement or treatment of Th2-mediated immune diseases, It is expected to be useful for industrial applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition comprenant de la miquélianine en tant que principe actif pour prévenir, soulager ou traiter des maladies immunitaires médiées par Th2. Une composition selon la présente invention s'est avérée présenter un excellent effet antiallergique. Plus en détail, la miquélianine a été identifiée pour restreindre la génération d'interleukine-2 (IL-2), d'interleukine-4 (IL-4), d'interleukine-5 (IL-5), et/ou d'interleukine-13 (IL-13) alors que l'on testait son effet anti-allergique in vivo et ex vivo. En outre, la miquélianine s'est avérée avoir l'effet de produire des IgE et d'empêcher la prolifération des lymphocytes T. Par conséquent, la composition selon la présente invention est censée trouver des applications utiles dans la mise au point d'un agent thérapeutique, d'un aliment fonctionnel de santé, et d'un produit cosmétique pour la prévention, le soulagement ou le traitement de maladies immunitaires médiées par Th2.
PCT/KR2018/008664 2017-08-30 2018-07-31 Composition comprenant de la miquelianine en tant que principe actif pour la prévention ou le traitement d'une maladies immunitaire médiée par th2 WO2019045286A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0110429 2017-08-30
KR20170110429 2017-08-30
KR1020180088860A KR102109503B1 (ko) 2017-08-30 2018-07-30 미?리아닌을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
KR10-2018-0088860 2018-07-30

Publications (2)

Publication Number Publication Date
WO2019045286A2 true WO2019045286A2 (fr) 2019-03-07
WO2019045286A3 WO2019045286A3 (fr) 2019-04-18

Family

ID=65525715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/008664 WO2019045286A2 (fr) 2017-08-30 2018-07-31 Composition comprenant de la miquelianine en tant que principe actif pour la prévention ou le traitement d'une maladies immunitaire médiée par th2

Country Status (1)

Country Link
WO (1) WO2019045286A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2229940T1 (sl) * 2009-03-20 2016-01-29 Bioxtract S.A. Farmacevtski sestavek s protivnetnimi in antihistaminskimi lastnostmi
KR20160057716A (ko) * 2014-11-14 2016-05-24 한림대학교 산학협력단 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물
KR20160101732A (ko) * 2015-02-17 2016-08-26 유한회사한풍제약 포도잎 추출물 또는 이로부터 분리한 퀘르세틴-3-o-글루쿠로니드를 유효성분으로 함유하는 뇌질환의 예방, 개선 또는 치료를 위한 조성물

Also Published As

Publication number Publication date
WO2019045286A3 (fr) 2019-04-18

Similar Documents

Publication Publication Date Title
WO2016144139A2 (fr) Composition pour prévenir ou traiter des maladies inflammatoires, comprenant des vésicules extracellulaires dérivées de bactéries d'acide lactique comme principes actifs
WO2012165731A1 (fr) Nouvelle utilisation du riz, du son de riz ou d'un extrait de balle en tant qu'antagoniste de récepteur de l'histamine
WO2019124863A1 (fr) Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique
WO2020013610A1 (fr) Composition pour la prévention, l'atténuation ou le traitement de maladies cutanées allergiques, contenant, en tant que principe actif, un extrait de fruits de gardénia desquels des pigments sont retirés
KR101831883B1 (ko) 이소세코타나파솔라이드를 유효성분으로 함유하는 가려움증 억제 및 완화용 화장료 조성물
WO2024071736A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies allergiques, contenant des cellules mortes de streptococcus pyogenes ou une protéine spea
KR101843574B1 (ko) 영실 발효 추출물을 유효성분으로 포함하는, Th2-매개 면역질환의 예방 또는 치료용 조성물
KR101756020B1 (ko) 물오리나무 발효추출물을 포함하는 아토피피부염 예방, 개선, 또는 치료용 조성물
WO2019045286A2 (fr) Composition comprenant de la miquelianine en tant que principe actif pour la prévention ou le traitement d'une maladies immunitaire médiée par th2
WO2015034247A1 (fr) Composition contenant un composé de monoacétyldiacylglycérol comme principe actif pour prévenir ou traiter la dermatite atopique
KR101666524B1 (ko) 초과(Amomi Tsao-ko)로부터 분리된 화합물 및 이의 항염 용도
KR101890017B1 (ko) 영실 및 황금 추출물을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
KR102120758B1 (ko) 커피 추출물을 유효성분으로 포함하는 알러지성 질환의 예방, 개선 또는 치료용 조성물
WO2020111540A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du vieillissement ou de maladies associées au vieillissement, comprenant un complexe d'anthocyanine-polysaccharide en tant que principe actif
KR20190024678A (ko) 미?리아닌을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
WO2019031655A1 (fr) Composition comprenant du thymol comme principe actif pour prévenir ou traiter les rides de la peau ou la dermatite atopique
KR101843573B1 (ko) 효소처리 영실 추출물을 유효성분으로 포함하는 Th2-매개 면역질환의 예방 또는 치료용 조성물
WO2017074058A1 (fr) Composition contenant un extrait de fermentation de rosa multiflora comme principe actif pour prévenir ou traiter des maladies immunitaires médiées par les th2
WO2017099413A1 (fr) Composition comprenant un extrait de fruit de rosa multiflora traité par enzyme en tant que substance active pour prévenir ou traiter une maladie immunologique médiée par th2
WO2014069836A1 (fr) Composition d'antagoniste de récepteur d'histamine contenant du policosanol comme ingrédient actif
WO2019078606A2 (fr) Composition anti-inflammatoire, antiallergène et améliorant la dermatite atopique utilisant un extrait de sargassum horneri ou un extrait d'ecklonia veine
EP1157693A1 (fr) Utilisation de l'epigallocatechin 3-o-(3-o-methyl) gallate et/ou l'epigallocatechin 3-o-(4-o-methyl) gallate pour le traitement de l'allergie et/ou l'inflammation
WO2023008615A1 (fr) Composition pour inhiber la sécrétion de sébum comprenant de l'acide ellagique en tant que principe actif
WO2020222506A1 (fr) Composition orale comprenant un aptamère en tant que principe actif
KR20190003415A (ko) 효소처리 엘라그산을 유효성분으로 포함하는 Th2-매개 면역질환 또는 염증성 질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18851356

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18851356

Country of ref document: EP

Kind code of ref document: A2